Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.35: EMPLOYEE BENEFIT PLANS (CONTINUED) Asset information CATEGORY OF ASSETS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Corporate bonds 51% 51% Equity shares of listed companies 49% 49% Total 100% 100% Summary of actuarial assumptions PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Discount rate 7.50% p.a. 8.00% p.a. Expected rate of return on plan assets 8.00% p.a. 8.00% p.a. Salary escalation rate 4.50% p.a. 4.50% p.a. Discount rate: The discount rate is based on the market yields prevailing in Mexico as at the balance sheet date for the estimated term of the obligations. Expected rate of return on plan assets: This is based on our expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations. Salary escalation rate: The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors. Amounts recognized in current year and previous four years PARTICULARS AS AT / FOR THE YEAR ENDED 31 MARCH 2015 2014 2013 2012 2011 Defined benefit obligation 252 253 301 272 319 Plan assets 68 110 125 186 247 Surplus / (deficit) (184) (143) (176) (86) (72) Experience Adjustment on Plan Liabilities 25 (28) 29 (33) 16 Experience Adjustment on Plan Assets (2) (5) - (9) (23) 2.35.3 Other Benefits Provident fund benefits In India, certain categories of employees of the Company receive benefits from a provident fund, a defined contribution plan. Both the employee and employer each make monthly contributions to a government administered fund equal to 12% of the covered employee’s qualifying salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed ` 492 and ` 411 to the provident fund plan during the year ended 31 March 2015 and 2014, respectively. Superannuation benefits In India, certain categories of employees of the Company participate in superannuation, a defined contribution plan administered by the Life Insurance Corporation of India. The Company makes annual contributions based on a specified percentage of each covered employee’s salary. The Company has no further obligations under the plan beyond its annual contributions. The Company contributed ` 68 and ` 63 to the superannuation plan during the year ended 31 March 2015 and 2014, respectively. Other contribution plans In the United States, the Company sponsors a defined contribution 401(k) retirement savings plan for all eligible employees who meet minimum age and service requirements. The Company contributed ` 195 and `162 to the 401(k) retirement savings plan during the years ended 31 March 2015 and 2014, respectively. The Company has no further obligations under the plan beyond its annual matching contributions. In the United Kingdom, certain social security benefits (such as pension, unemployment and disability) are funded by employers and employees through mandatory National Insurance contributions. The contribution amounts are determined based upon the employee’s salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed ` 151 and ` 151 to the National Insurance during the years ended 31 March 2015 and 2014, respectively. 212
Consolidated Financial Statements Annual Report 2014 - 15 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.35: EMPLOYEE BENEFIT PLANS (CONTINUED) Compensated leave of absence The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized compensated absences and utilize it in future periods or receive cash in lieu thereof as per Company policy. The Company records an obligation for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this benefit was ` 616 and ` 463 as at 31 March 2015 and 2014, respectively. Long term incentive plan Certain senior management employees of the Company participate in a long term incentive plan which is aimed at rewarding the individual, based on performance of such individual, their business unit / function and the Company as a whole, with significantly higher rewards for superior performances. The total liability recorded by the Company towards this plan was ` 323 as of 31 March 2015. 2.36: HEDGES OF FOREIGN CURRENCY RISKS, INTEREST RATE RISKS AND DERIVATIVE FINANCIAL INSTRUMENTS The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, British pounds sterling, Russian roubles, Venezuelan bolivar and Euros, and foreign currency debt in U.S. dollars, Russian roubles and Euros. The Company uses forward contracts, option contracts and swap contracts (derivatives) to mitigate its risk of changes in foreign currency exchange rates. Further, the Company also uses non-derivative financial instruments as part of its foreign currency exposure risk mitigation strategy. In respect of all of its foreign exchange derivative contracts, the Company has recorded, as part of foreign exchange gains and losses, a net gain of ` 2,235 and a net loss of ` 430 for the years ended 31 March 2015 and 2014, respectively. Hedges of highly probable forecasted transactions The Company classifies its derivative contracts that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded as part of reserves and surplus within the Company’s “hedging reserve”, and re-classified in the statement of profit and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion is immediately recorded in the statement of profit and loss. The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for the hedge of foreign currency risk associated with highly probable forecasted transactions and, accordingly, applies cash flow hedge accounting for such relationships. Re-measurement gain / loss on such non-derivative financial liabilities is recorded as part of reserves and surplus within the Company’s “hedgingreserve”, and re-classified in the statement of profit and loss as revenue in the period corresponding to the occurrence of the forecasted transactions. In respect of the aforesaid hedges of highly probable forecasted transactions, the Company has recorded, in reserves and surplus, a net gain of ` 99 and a net loss of ` 1,651 for the years ended 31 March 2015 and 2014, respectively. The Company also recorded, as part of revenue, a net gain of ` 300 and a net loss of ` 1,093 during the years ended 31 March 2015 and 2014, respectively. The net carrying amount of the Company’s “hedging reserve” in reserves and surplus before adjusting for tax impact was a loss of ` 1,805 as at 31 March 2015, as compared to a loss of ` 1,904 as at 31 March 2014. The table below summarizes the periods when the forecasted cash flows associated with hedging instruments that are classified as cash flow hedges, are expected to occur: PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Cash flows in U.S. Dollars (figures in equivalent rupee millions) Not later than one month 2,969 1,797 Later than one month and not later than three months 5,625 3,595 Later than three months and not later than six months 8,594 5,392 Later than six months and not later than one year 7,188 9,287 Later than one year 3,438 9,886 27,814 29,957 Cash flows in Roubles (figures in equivalent rupee millions) Not later than one month 27 - Later than one month and not later than three months 54 - Later than three months and not later than six months 81 - Later than six months and not later than one year 161 - 323 - 213
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Statutory Reports • Board’s Rep
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Standalone Financial Statements Ann
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 213: Consolidated Financial Statements A
Page 227 and 228: Notice Annual Report 2014 - 15 NOTI
Page 229 and 230: E-Voting Annual Report 2014 - 15 IN
Page 231: Dr. Reddy’s Laboratories Limited
Page 235 and 236: The future belongs, not to those wh
show all

Good Health Can’t Wait.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?